Synonyms: PF-07304814 | PF07304814
Compound class:
Synthetic organic
Comment: PF-07304814 is a SARS-CoV-2 3CL protease (Mpro) inhibitor from Pfizer. The structure of PF-07304814 is identical to that of the INN lufotrelvir (from proposed list 125, July 2021). PF-07304814's phosphate group (which improves solubility) is cleaved in vitro to release the active antiviral PF-00835231 [1-2]. PF-00835231 was originally developed as a SARS-CoV Mpro inhibitor in response to the 2002-2003 outbreak [3]. Like remdesivir, PF-07304814 is administered by intravenous infusion.
|
|
Bioactivity Comments |
PF-00835231 potently inhibits replication of SARS-CoV-2 of the two major clades from clinical isolates in A549+ACE2 cells, and was statistically more potent than remdesivir [2]. |